Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1696 to 1710 of 8916 results

  1. Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]

    In development Reference number: GID-TA11410 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development Reference number: GID-TA10700 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  4. Third molars (impacted) - prophylactic removal [ID898]

    In development Reference number: GID-TAG525 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]

    Awaiting development Reference number: GID-TA10682 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]

    Awaiting development Reference number: GID-TA11343 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156]

    Awaiting development Reference number: GID-TA11087 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Aprocitentan for treating resistant hypertension [TSID10395]

    Awaiting development Reference number: GID-TA11459 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    Awaiting development Reference number: GID-TA11560 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210]

    Awaiting development Reference number: GID-TA11182 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development Reference number: GID-TA10046 Expected publication date:  22 November 2017

    Technology appraisal guidance
    In development

  14. Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]

    In development Reference number: GID-TA10089 Expected publication date:  15 November 2017

    Technology appraisal guidance
    In development

  15. Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development